ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1742

Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity

Natasja Stæhr Gudman1, Anne Friesgaard Christensen2, Grith Lykke Sørensen3, Anne C. Bay-Jensen4, Anne Sofie Siebuhr5, Morten Asser Karsdal6, Heidi Lausten Munk7, Leif Ejstrup8, Anne Gitte Loft9 and Peter Junker10, 1Nordic Bioscience A/S, Herlev, Denmark, 2Rheumatology, Odense University Hospital, Odense, Denmark, 3Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark, 4Biomarkers and Research, Rheumatology, Nordic Bioscience, Herlev, Denmark, 5Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 6Research & Development, Nordic Bioscience, Herlev, Denmark, 7Department of Rheumatology, Odense University Hospital, Odense, Denmark, 8Odense University Hosp, SDR Blvd, Odense, Denmark, 9Department of Rheumatology, Vejle Hospital, Vejle, Denmark, 10University of Southern Denmark, Odense, Denmark

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Collagen, psoriatic arthritis and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: AxSpA
and PsA are core members of the spondyloarthritis
complex. One cardinal characteristic shared by these two conditions is
increased remodeling of bone and soft connective tissue in and around
peripheral joints, axial skeleton and entheseal
insertions leading to synovitis, enthesitis
and ankylosis in advanced disease. Studies using seromarkers which reflect extracellular matrix constituent
metabolism may provide insight into the activity and dynamics of
connective remodeling and thereby pave the way for improved diagnostics and
management. The aims of this investigation were to study C1M and C3M, which
reflect the turnover of collagen I and III, in order to assess their
utility as diagnostic and disease activity markers.

Methods: Ninety-nine patients with PsA,
110 with axSpA and 120 healthy control subjects were
included. Demographic and clinical disease measures were recorded.C1M and C3M
were quantified using in house competitive ELISAs. Biomarker results are
presented as median with 95% CI. Mann Whitney test was applied for inter-group
comparisons and correlations were studied using Spearmans
test.  Receiver operator characteristics (ROC) curve analysis was carried
out to evaluate the diagnostic potential of the biomarkers.

Results: C1M and C3M were significantly increased in
both axSpA and PsA as
compared with healthy controls (Figure). Thus, in axSPA
C1M and C3M amounted to 77.6 (71.3-84.6)ng/ml and
27.7 (26.2-29.7)ng/ml respectively, in PsA to 85.6 (78.2-96.2)ng/ml and
28.7 (26.7-31.0)ng/ml versus controls 48.3(43.3-53.2)
and 20.9 (20.0-21.7) respectively. C1M and C3M levels did not differ
significantly between axSpA and PsA.
Serum levels of C1M and C3M were not affected by treatment, or smoking status,
but SpA HLA-B27+ patients had significantly higher
levels of both C1M (p=0.001) and C3M (p=0.006) compared to HLAB-27- SpA patients. C1M was significantly correlated with DAS28 (PsA: r=0.22, p=0.028, SpA:
r=0.40, p<0.0001) and ASDAS (PsA: r=0.29, p=0.003,
SpA:r=0.35, r=0.0002). Also
C3M was significantly correlated with DAS28 (PsA:
r=0.22, p=0.025, SpA: r=0.74, p<0.0001) and ASDAS
(PsA: r=0.32, p=0.0013, SpA:
r=0.216, p=0.026). C1M and C3M were highly correlated (p>0.0001 in all
groups) but they did not correlate with demographics including age, BMI or
gender. Segregation between healthy and diseased based on C1M levels resulted
in an AUC of 0.83 for PsA (0.76-0.86) and 0.79
(0.73-0.84) for SpA. C3M could also segregate between
healthy and diseased with an AUC of 0.77 (0.71-0.82) for PsA
and 0.78 (0.72-0.83) for SpA. 

Conclusion: These findings indicate that soft connective
tissue remodeling is equally increased in axSpA and PsA reflecting disease activity and that collagen type
I and III turnover are mediated by closely coupled mechanisms. ROC curve
analyses suggest that both C1M and C3M may be useful for diagnostic purposes in
axSpA and PsA.

Picture2.jpg


Disclosure: N. S. Gudman, Nordic Bioscience Diagnostic, 3; A. F. Christensen, None; G. L. Sørensen, None; A. C. Bay-Jensen, Nordic Bioscience Diagnostic, 1,Nordic Bioscience Diagnostic, 3; A. S. Siebuhr, None; M. A. Karsdal, Nordic Bioscience Diagnostic, 1,Nordic Bioscience Diagnostic, 3; H. L. Munk, None; L. Ejstrup, None; A. G. Loft, None; P. Junker, None.

To cite this abstract in AMA style:

Gudman NS, Christensen AF, Sørensen GL, Bay-Jensen AC, Siebuhr AS, Karsdal MA, Munk HL, Ejstrup L, Loft AG, Junker P. Fingerprint Biomarkers of Type I and III Collagen in Axial Spondyloarthropathy (axSpA) and Psoriatic Arthritis (PsA). Association with Disease Activity and Diagnostic Capacity [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/fingerprint-biomarkers-of-type-i-and-iii-collagen-in-axial-spondyloarthropathy-axspa-and-psoriatic-arthritis-psa-association-with-disease-activity-and-diagnostic-capacity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fingerprint-biomarkers-of-type-i-and-iii-collagen-in-axial-spondyloarthropathy-axspa-and-psoriatic-arthritis-psa-association-with-disease-activity-and-diagnostic-capacity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology